Concert Pharmaceuticals Hits $4 Million Milestone in GSK Alliance
(Page 2 of 2)
of Atripla, Gilead Sciences’ (NASDAQ: GILD) once-a-day combo of HIV treatments efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Gilead’s product brought in sales of $2.9 billion last year. “That drug has been successful because it’s simple for patients to take,” Tung says.
Concert’s goal is to begin extensive human testing of CTP-298 next year. Tung says Concert and Glaxo are unable to predict the development timeline on the combo because they’re still working out the logistics.
To underscore the potential of its deuterium platform in other diseases, Concert also announced today that it had selected two other clinical candidates: CTP-499 for diabetic nephropathy and C-21191 for spasticity.
Patients with diabetic nephropathy—a type of kidney damage—are at high risk of needing dialysis or transplants. “This is a huge area because of the epidemic of diabetes,” Tung says. So Concert applied its deuterium technology to an existing drug that was originally designed to improve blood flow in patients with poor circulation. Concert’s scientists hope to prove that their deuterium-modified drug will combat the inflammation and tissue hardening that nephropathy causes.
Spasticity is a type of nerve pain that’s common in patients with multiple sclerosis, stroke, and other neurological disorders. C-21191 is based on an old discovery of a molecule that hits known receptors in the brain for modulating pain, but that’s useless because it doesn’t last long enough in the body. Tung says he hopes C-21191 will further prove that deuterium is “a way of rescuing drugs” that would otherwise be hampered by their short life in the human body.
Tung, a chemist by training, knows from experience that patience can pay off when it comes to studying entirely new therapeutic pathways. He once worked as a chemist at Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX), where he helped to invent technology used to create telaprevir, Vertex’s hepatitis C drug that was recently approved to huge fanfare.
“Seeing that go forward is very rewarding,” he says. Drug development, he concludes, “is long, arduous, difficult. Being innovative is what will keep this industry alive.”